mRNA

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

Cell and gene therapies
#Cell and gene therapy #mRNA #pDNA #Webinar

Early phase support for plasmid DNA supply to secure future manufacturing

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material. Building a robust supply of GMP-grade pDNA requires that quality be a… Read More

Webinar date:
Brought to you by Catalent
#Webinars

Tick bite
#Biomarkers #Genetic profiling #Immunity #Lyme Disease #mRNA #Omics #RNA sequencing

Genetic profiling of Lyme disease could bring new therapeutic targets 

Researchers have identified 35 genes associated with long-term Lyme disease that could potentially be used as biomarkers to diagnose patients with the condition.  The findings, from the Icahn School of Medicine at Mount Sinai in New York and published in the journal Cell… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: How to resolve barriers to CGT discovery

Stream this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. The webinar was presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production… Read More

#News

Lipid nanoparticle mRNA vaccine
#CPHI Excellence in Pharma Award #Drug delivery #mRNA #Polymer-based drug delivery

Polymer-based drug delivery system for mRNA wins award

A new polymer-based drug delivery system for mRNA and other nucleic acids has won the CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”.  The system was developed by Evonik Health Care together with researchers at Stanford University.  Developed together with Professors… Read More

#News

#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Merck and Moderna to jointly develop personalised cancer vaccine 

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More

#Cancer Research #News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Overcome barriers to CGT innovation

Watch this free webinar, hosted by DDW and supported by Catalent, which will be presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based… Read More

#News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Exclusive webinar: How to remove the barriers to CGT innovation

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Secure future manufacturing for advanced therapies

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

#Biomarkers #Cancer research #Click chemistry #Covid-19 #Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #mRNA #Oncology #Our Future Health #Pancreatic cancer

This week in drug discovery (24-28 October)

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Optimise plasmid production process and supply

This on-demand webinar, hosted by DDW and supported by Catalent, is presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene… Read More

#News

Lipid nanoparticle mRNA vaccine entering a human cell
#Covid-19 #Covid-19 treatment #hACE2 #mRNA #SARS-CoV-2

Could mRNA become a ‘universal’ Covid-19 treatment? 

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses.  A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2… Read More

#Covid-19 #News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar addresses CGT challenges and how to resolve them

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this on-demand webinar – Early phase support for plasmid DNA supply… Read More

#News